Building a $500 Pharma Portfolio: Two High Growth Stocks for Long-Term Wealth

When constructing a modest investment portfolio, the pharmaceutical sector offers compelling opportunities that combine strong appreciation potential with defensive characteristics. For investors with just $500 to deploy, the key is identifying high growth stocks that can drive returns while also including stable dividend payers to offset market downturns. The healthcare industry presents an ideal environment for this balanced approach, particularly when selecting companies positioned in booming segments like GLP-1 therapeutics.

Novo Nordisk: Capturing the GLP-1 Market Expansion

Novo Nordisk represents a classic high growth stock opportunity within the pharmaceutical space. This Denmark-based global pharmaceutical leader has emerged as one of two dominant players in the rapidly expanding GLP-1 drug market, alongside Eli Lilly. The company’s weight management medication Wegovy and diabetes treatments Ozempic and Rybelsus have created a powerful revenue engine positioned to capture years of market expansion.

The growth trajectory tells a compelling story. In fiscal 2025, the company’s diabetes and obesity care division generated a 7% sales increase, with obesity care medications specifically surging 26%. Looking ahead to 2026, management is guiding for 5% to 13% sales growth, supported by favorable shifts in rebate provisions within the U.S. market. Perhaps most importantly, analysts project the GLP-1 market will balloon to $254 billion by 2034—a compound annual growth rate of 17%—suggesting this therapeutic category remains in early expansion phases.

The valuation presents another attractive angle. Trading at just 13 times earnings, Novo Nordisk offers a rare combination of high growth stocks characteristics—strong market tailwinds and earnings expansion—at a reasonable price. At approximately $49 per share, $500 in capital would secure roughly 10 shares of this cornerstone holding.

AbbVie: Pairing Growth with Defensive Power

To create a well-rounded portfolio from your $500 allocation, complementing the Novo Nordisk position with AbbVie addresses the defensive side of the equation. Spun off from Abbott Labs in 2013, AbbVie has consistently demonstrated its ability to weather market storms while delivering substantial returns.

During the 2022 bear market, when the broader S&P 500 declined 18%, AbbVie climbed 24%—a clear demonstration of its protective qualities. More impressively, the company has maintained an unbroken 13-year streak of dividend increases, currently yielding 3.1%. Over the past decade, AbbVie has delivered an average annual return of 20% with dividends reinvested, substantially outpacing the market’s general performance.

Yet AbbVie shouldn’t be viewed merely as a defensive position. The company is successfully transitioning from its dependency on Humira—facing a patent cliff in 2028—toward powerful next-generation drugs. Skyrizi and Rinvoq demonstrated the strength of this transition, with net revenue gains of 33% and 30% respectively in 2025. At 15 times forward earnings, the company remains reasonably valued, and analysts anticipate further 11% upside over the coming year.

Constructing Your Portfolio Strategy

With $500 to invest, one compelling approach involves allocating roughly half toward each position: acquiring one share of AbbVie coupled with five or six shares of Novo Nordisk creates a balanced portfolio structure. This allocation pairs meaningful exposure to high growth stocks—specifically Novo Nordisk’s participation in the expanding GLP-1 market—with AbbVie’s proven dividend reliability and demonstrated recession resilience.

The pharmaceutical sector uniquely allows investors to simultaneously access explosive growth opportunities and steady income generation. By thoughtfully combining these two companies, a modest capital base can establish a foundation for long-term wealth accumulation that addresses both growth aspirations and stability requirements.